The purified protein derivative (PPD) skin test for
Significant impediments to global tuberculosis (TB) control include limitations of current diagnostic tests [1] . Identification of Mycobacterium tuberculosisinfected individuals is especially difficult in tropical environments, where bacille Calmette-Guérin (BCG) coverage is high and environmental mycobacteria are commonly encountered. The conventional purified protein derivative (PPD) skin test has unknown sensitivity and specificity for detection of M. tuberculosis infection, and its response after BCG vaccination varies by latitude [2] . New tests are required to assist development of entry criteria for trials of new generation TB vaccines and to make preventive TB treatment feasible where resources are scarce.
Certain highly immunogenic secreted antigens of M. tuberculosis, such as ESAT-6 and CFP-10, offer hope for more specific diagnosis of M. tuberculosis infection. Their genes were deleted from Mycobacterium bovis in the development of BCG and are found in few environmental mycobacteria [3, 4] . Immunoassays for IFNg production in response to ESAT-6/CFP-10 have been tested in patients with TB, their contacts, and members of the general community. In nontropical settings, they have been shown to be relatively sensitive in identifying TB cases (180%), approaching 100% specificity in general communities where it is not endemic, and have proven capable of distinguishing persons with positive PPD skin test results owing to previous BCG vaccination [5] [6] [7] . That ESAT-6 and CFP-10 are secreted by some nontuberculous mycobacteria [8] has led to the suggestion that the high prevalence of such organisms in the environment in tropical countries may render the assays nonspecific [9] . We hypothesized that measurement of the immune responses to ESAT-6 and CFP-10 offers improved specificity over PPD skin testing for the diagnosis of M. tuberculosis infection in a tropical setting, without compromising sensitivity. Therefore, we compared the IFN-g responses to ESAT-6/CFP-10 by enzyme-linked immunospot assay (ELISPOT) with the IFN-g responses to PPD by ELISPOT and the delayed hypersensitivity response (DTH) to PPD by skin testing in The Gambia.
PATIENTS, MATERIALS, AND METHODS
Participants. Sputum smear-positive TB index case patients aged 115 years old were recruited in Greater Banjul, The Gambia, an area where 450,000 people reside and where the incidence of newly diagnosed sputum smear-positive TB is ∼80 cases per 100,000 population per year [10] . Included patients had 2 sputum samples test positive for acid-fast bacilli by ZiehlNeelson stain and M. tuberculosis on culture. They were identified at the major government health center and the Medical Research Council Laboratories' (MRC Labs) outpatient clinic, examined, had chest radiography findings reported by 2 specialist physicians, and were invited, after counseling, to undergo an HIV test.
Household contacts were included if they were у6 months old and lived the majority of the time on the same compound as the case patient. They were not eligible if they had been treated for TB in the past year or if they were recruited 60 days after the patient had been, and they were excluded if TB was diagnosed within 1 month of recruitment and if they had been coughing longer than the patient. Subjects were brought to MRC Labs, invited to give informed consent, interviewed, and examined, and a blood sample was obtained for ELISPOT and HIV testing. Fresh samples from all participants were processed on site. To meet a logistic ceiling, a maximum of 12 contacts per day were screened; the others were randomly excluded. Subject details were recorded on a standardized form.
Contacts underwent a PPD skin test (2 TU, PPD RT23; Statins Serum Institut). Induration was recorded at 48-72 h. Regular spot checks were performed in addition to a second reading on 100 consecutive skin tests. Subjects with a positive skin test result (mean induration diameter, у10 mm) were offered to undergo chest radiography, and those with symptoms underwent clinical assessment. Persons with TB disease were referred to the National Programme for free treatment. There is no current practice of preventive treatment in The Gambia. This study was approved by The Gambia Government/MRC joint Ethics Committee.
Laboratory procedures. Sputum smears were prepared and stained with auramine-phenol [11] , and the findings were confirmed by Ziehl-Neelsen staining. Decontaminated specimens were inoculated into 1 slope each of Lowenstein-Jensen medium containing glycerol and sodium pyruvate, respectively, and one vial of BACTEC 9000 MB media for isolation of M. tuberculosis. All mycobacterial cultures were identified and confirmed by standard procedures.
The ex vivo ELISPOT assays for IFN-g were performed as described elsewhere [12] . For this study, synthetic sequential peptides spanning the length of ESAT-6 and CFP-10 (ABC; Imperial College) were used. Each peptide was 15 amino acids long and overlapped its adjacent peptide by 10 residues. ESAT-6 and CFP-10 peptides, used at 5 mg/mL, were each divided equally and sequentially into 2 pools of 8 or 9 peptides (4 pools in total). PPD (M. tuberculosis, RT49; Statins Serum Institut) was used at 10 mg/mL. The positive control was phytohemag- glutinin (Sigma-Aldrich). All antigens were tested in duplicate wells.
Assays were scored by an ELISPOT counter (AID-GmbH). The spot-forming unit (SFU) numbers counted in each well were automatically entered into a database. Supplementary details were added by double data entry by 2 immunologists blinded to subject details. Positive test wells were predefined as containing у10 SFUs more than-and at least twice as many as-negative control wells. For a positive ESAT-6/CFP-10 result, it was necessary for у1 pools of overlapping peptides to be positive. Phytohemagglutinin-positive control wells were set to у150 SFUs above negative control wells. Negative control wells were required to have !30 SFUs.
Testing for HIV-1 or HIV-2 infection was performed using competitive ELISAs (Wellcome Laboratories) and Western blot test (Diagnostics Pasteur).
Ascertainment of exposure. Various factors were assessed as surrogate markers of M. tuberculosis exposure. Similar to a previous Gambian study [13] , TB contacts were categorized according to where they slept: in the same bedroom as the patient, in a different bedroom in the same house, or in a different house. The average amount of time spent daily on the compound with the patient was also assessed. The following TB case factors were assessed: duration of cough, sputum smear grade, and number of diseased quadrants on a chest radiograph.
Data management and analysis. All data were entered via double data entry into an Access database and checked for errors. A random effects logistic regression model, taking into account household clustering, was used to assess the relationship between risk factors and test results. Results were reported as unadjusted and adjusted ORs and their 95% CIs. The likelihood ratio test was used to test for interaction and for trend. All statistical analyses were conducted by Stata software, version 7 (Stata).
RESULTS

From 2 May 2002 to 24
April 2003, a total of 143 cases and 135 households were investigated. Of 1059 eligible case contacts, 983 gave consent, and 856 were selected to undergo ELIS-POT and had an adequate blood specimen available. Of these, 735 contacts (86%) of 130 cases had a PPD skin test result plus ELISPOT results that met inclusion criteria (tables 1 and 2). Skin tests from 231 subjects were read twice, giving a k statistic of 0.83 and 95% concordance.
Overall, 476 subjects (65%) had positive PPD ELISPOT results, 300 (41%) had positive PPD skin test results, and 218 (30%) had positive ESAT-6/CFP-10 ELISPOT results. Only 15 (2%) subjects were ESAT-6/CFP-10 positive and PPD ELISPOT negative; 56 (8%) had positive ESAT-6/CFP-10 ELISPOT results and negative PPD skin test results, and 240 (33%) had positive PPD ELISPOT results and negative PPD skin test results ( figure  1) .
The univariable odds of a result being positive for each test by various possible surrogate measures of increasing exposure to M. tuberculosis are presented in table 3. All of the test results were significantly more likely to be positive in contacts with closer sleeping proximity to the patient. This increase was most dramatic for the PPD skin test. The odds of having positive PPD ELISPOT results was higher for those subjects who reported spending 112 h on average per day on the compound with the patient, compared with the baseline of р4 h. The duration of cough of the patient and the number of diseased quadrants on a chest radiograph were not useful measures.
The odds of test positivity were increased for the presence of a BCG scar for PPD ELISPOT and PPD skin test, but this was not statistically significant (OR, 1.37 [95% CI, 0.95-1.97] and 1.1 [95% CI, 0.75-1.60], respectively). The odds of test positivity decreased with the presence of a BCG scar for the ESAT-6/CFP-10 ELISPOT, but this was also not significant (OR, 0.74; 95% CI, 0.5-1.1).
In the multivariable analysis, the odds of having positive ESAT-6/CFP-10 ELISPOT results for those sleeping in the same room as the patient relative to those in a different house, adjusted for age, sex, and ethnicity, remained significant (OR, 1.85; 95% CI, 1.06-3.23). After adjustment for age, sex, ethnicity, and time spent on the compound with the patient, the odds of having positive PPD ELISPOT results for those in the same room as the patient relative to those sleeping in a different house was no longer significant (OR, 1.5; 95% CI, 0.85-2.64). There was also an interaction found between smear grade and sleeping proximity ( ): for those sleeping in a different P p .04 house, the OR for smear grade 3+ was 3.05 (95% CI, 1.43-6.53), whereas for those sleeping in a different room or the same room, the OR for smear grade 3+ was close to 1. For PPD skin test positivity, sleeping proximity and sputum smear grade remained independent risk factors, and there was a significant interaction between age and sex. The adjusted OR for sleeping in a different room relative to a different house was 2.12 (95% CI, 1.29-3.48), and for sleeping in the same room relative to a different house, it was 4.74 (95% CI, 2.67-8.46). The distributions of age and sex by proximity, together with ethnicity, are shown in table 4.
The proportions of subjects with positive PPD ELISPOT, ESAT-6/CFP-10 ELISPOT, or PPD skin test results across 3 exposure categories are shown graphically in figure 2, together with a matrix showing, within each category, the percentage of subjects with each combination of the test results. The proportion of subjects with positive ESAT-6/CFP-10 ELISPOT or PPD skin test results was not as high as the proportion with positive PPD ELISPOT results in any category. PPD skin test positivity diverged from ESAT-6/CFP-10 with increasing TB exposure, and from PPD ELISPOT with decreasing TB exposure. Consistent with the divergence between PPD skin test and ESAT-6/CFP-10 ELISPOT results, the percentage of subjects who had positive PPD skin test results and negative ESAT-6/ CFP-10 ELISPOT results increased from 11% of those sleeping in a different house from the patient to 32% ( ) of P ! .0001 those sleeping in the same room (figure 2). Consistent with the divergence of the 2 measures of PPD immune response, the percentage of subjects with positive PPD ELISPOT results and negative PPD skin test results increased from 22% of those sleeping in the same room as the patient to 41% of those sleeping in a different house (
). The percentage of P p .011 subjects with positive PPD skin test results and negative PPD ELISPOT results was 8.7% overall and did not change significantly across the exposure categories ( ). Almost one-P p .17 third of subjects (18 [31%] of 58 subjects) who slept in a different house from the patient and who had positive ESAT-6/CFP-10 ELISPOT results had negative PPD skin test results.
DISCUSSION
These results provide a large-scale evaluation of the ELISPOT assay alongside the PPD skin test in TB contacts 16 months old in a tropical country. The ELISPOT assay performed predictably: with increasing recent exposure to M. tuberculosis and a likely background of intense mycobacterial exposure, the percentage of subjects with positive PPD results was consistently high and increased slightly, whereas the percentage of those with positive ESAT-6/CFP-10 results was less in all categories and also increased. Only 2% of subjects were ESAT-6/CFP-10 positive and PPD negative. It can be concluded that the ESAT-6/CFP-10 ELISPOT assay improved specificity over PPD ELIS-POT. The PPD skin test results showed the most marked change across the M. tuberculosis exposure categories. With respect to the relationship between the PPD skin test and the 2 ELISPOT tests, 2 key findings from this study provide valuable insights: the percentage of subjects who had positive PPD skin test results and negative ESAT-6/CFP-10 ELISPOT results increased significantly with increasing M. tuberculosis exposure, and a large percentage of subjects, especially in the lowest exposure group, were PPD ELISPOT positive and PPD skin test negative.
That the proportion of subjects with positive PPD skin test results and negative ESAT-6/CFP-10 ELISPOT results increased with increasing M. tuberculosis exposure (11%-32%) supports the assertion that 2 M. tuberculosis-specific antigens may not be sufficient for the diagnosis of M. tuberculosis infection [14] . Comparison of the 2 ELISPOT tests also provides more subtle evidence for a sensitivity loss for ESAT-6/CFP-10 ELISPOT: the difference in PPD ELISPOT positivity between those sleeping in a different room and those sleeping in the same room as the patient was similar to that for ESAT-6/CFP-10 ELISPOT (9.2% and 8.0%, respectively), but it arose from a much higher baseline level (the lowest exposure category). The discovery of more M. tuberculosis-specific reagents may lead to increased sensitivity. Antigen mining from the M. tuberculosis genome has been used to identify potentially useful diagnostic antigens for M. bovis in cattle [15] . A study of an outbreak in England suggested high sensitivity for ESAT-6/CFP-10 by ELISPOT, although the source patient had been coughing for more than a year, and the cutoff for positivity was set at 5 spots above background [16] . Even in a study of the size reported here, the number of subjects is insufficient for the sensitivity analysis required to precisely define the number of spots for a cutoff in the diagnostic antigen or control wells.
The PPD ELISPOT-positive, PPD skin test-negative results are similar to those noted in Malawi by Black et al. [17] , where 63% of subjects aged 112 years had positive results of a 6-day assay and 37% had positive results of a PPD skin test at a 5-mm cutoff. They, like a previous Gambian study [13] , also noted a similar age and sex pattern with the PPD skin test as in our study. The discordance between the skin and blood responses may represent a specific DTH skin anergy caused by regular mucosal exposure to environmental mycobacteria. This is consistent with an experiment by Hoft et al. [18] showing oral ingestion of BCG caused inhibition of the DTH skin test while inducing significant increases in mycobacteria-specific IFN-g responses in PBMCs. That almost one-third of persons with positive ESAT-6/CFP-10 results in the lowest exposure category had negative PPD skin test results suggests a significant sensitivity problem for the skin test in these subjects, and a proportion of the dramatic change in positivity for the PPD skin test across the exposure categories is likely to be due to boosting of a suppressed DTH response by recent M. tuberculosis exposure [19] . Follow-up to identify secondary cases will give further indication of the relative sensitivities of these tests, as one would expect those who become secondary cases to be positive at recruitment.
That nearly 35% of all subjects tested had negative results of either ELISPOT test in a setting where TB is endemic with frequent environmental mycobacteria exposure may indicate waning over time. It is likely that the in vitro IFN-g ELISPOT detects recently activated lymphocytes with immediate effector function and effector memory cells that persist for a limited time in circulation once antigen is cleared [20, 21] . Antigens may well be differentially expressed by M. tuberculosis during the life cycle from early to stationary phase to latency. ESAT-6 and CFP-10 are secreted early in infection, although ESAT-6 gene expression has also been shown to occur under hypoxic, latency-type conditions [22] . Other antigens, such as a-crystallin, have been shown to be preferentially secreted by M. tuberculosis in hypoxia [23] . Therefore, early and latent infection may be best distinguished through measuring the immune response to different antigens. Such studies are under way in The Gambia.
The lack of a significant effect of BCG, as evidenced by a BCG scar, on either PPD test result is consistent with other studies [13, 19] . However, the measured odds may be an underestimate, because one-sixth or more of subjects provided with BCG at birth do not develop a visible scar [24] , and the OR for ESAT-6/CFP-10 ELISPOT (0.74; 95% CI, 0.5-1.1) indicates that BCG vaccination may offer some protection against M. tuberculosis infection.
These results are of particular importance for trials of newgeneration vaccines and preventive drug treatment strategies [25] . Vaccine trials require a realistic approach to recruitment in settings of endemicity. Concern about hypersensitivity reactions (the Koch phenomenon) demands avoidance of persons with active M. tuberculosis infection in early safety trials. At the present time, a combination of tests may be best: we suggest recruitment be limited to individuals who have negative results of HIV tests, PPD skin tests, and ESAT-6/CFP-10 ELISPOTs and who have normal chest radiograph findings plus no known TB contact. Later, randomized trials will be required to assess both the preventive and therapeutic effects of new vaccines. The ex vivo ELISPOT would offer real advantages over 6-day assays here; the result is likely to become negative as effector T lymphocytes wane in the months after clearance of infection. The specificity gain with the ESAT-6/CFP-10 ELISPOT test is of importance with respect to strategic preventive drug treatment. To cause a significant shift in the reproductive index of the epidemic, it would not be necessary to treat all persons who are infected. Furthermore, economic considerations, adverse drug reactions, and logistics demand that as many as possible of those treated are truly infected.
The ELISPOT assay has advantages over the skin test, which has to be read at 48-72 h and which is influenced by age and sex. Furthermore, injection of PPD in skin tests may sensitize the individual to M. tuberculosis antigens, affecting future diagnostic test results. Frequent ingestion of environmental mycobacteria requires diagnostic tests that use M. tuberculosisspecific antigens. Routine use of the ELISPOT where the burden of TB is greatest requires further research, including studies involving HIV-positive subjects, as well as a large investment to provide laboratory scientists and adequate laboratories. Although the ELISPOT is a relatively straightforward assay, technical expertise is required, especially to conduct cell separations. An alternative is whole-blood cultures and ELISA technology, which has been used to measure the IFN-g response to PPD but not to more specific antigens [26] . The ELISPOT should be an important part of the armamentarium for those planning therapeutic and vaccine trials.
